Aptevo Therapeutics (APVO)
(Delayed Data from NSDQ)
$0.71 USD
+0.03 (3.84%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.71 0.00 (0.55%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Aptevo Therapeutics Inc. [APVO]
Reports for Purchase
Showing records 21 - 40 ( 92 total )
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q22: APVO436 Progressing, New Clinical Trials to Start, Cash to Mid-2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Four New Remissions Seen in Phase 1b APVO436 Dose Expansion Trial for AML
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
A 2nd Phase 1b AML Patient Rendered Eligible for Allogeneic Transplant
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q21: APVO436 Showing Early Phase 1b Promise, Cash Through at Least 1Q23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Reasons to Sit Down with These Biotech Managements at the 2022 Conference
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
APVO436 Trial Attracts MD Anderson, Ruxience Thus Far Selling as Expected
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q21: APVO436 In Phase 1b, Cash Through 3Q22, PT to $36 from $50
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Publishes Positive Phase 1b APVO436 Data Showing Efficacy & RP2D Selected
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q21: APVO436 Phase 1 Complete, Funded Through 3Q22
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J